ARCT vs DBVT vs REGN vs SANA vs MRNA

For growth investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 2x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Arcturus Therapeutics Holdings Inc. (ARCT) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +43. 2%, compared to -81. 3% for Sana Biotechnology, Inc. (SANA). Over 10 years, the gap is even starker: MRNA returned +192. 2% versus SANA's -90. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 77β versus Sana Biotechnology, Inc. 's 2. 66β — meaning SANA is approximately 247% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 38% for Sana Biotechnology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.

(REGN) is pulling ahead at 1. 0% versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). On earnings-per-share growth, the picture is similar: Moderna, Inc. grew EPS 21. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — ARCT leads at 95. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SANA: 147.

0% to $8. 67.

In this comparison, REGN (0.

5% yield) pays a dividend. ARCT, DBVT, SANA, MRNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Sana Biotechnology, Inc. (SANA) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +91. 6%, SANA: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARCT is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; REGN is a mid-cap deep-value stock; SANA is a small-cap quality compounder stock; MRNA is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.